MD Biosciences said that this rapid response provides researchers with valuable data much more quickly than the traditional collagen-induced arthritis (CIA) model, which can take several weeks or more to produce similar histological results.
Data from the model shows the effectiveness of the arthritogenic antibodies, with mean histology scores and staining sections indicating the degree of erosion, hyperplasia and infiltration in the joint of the arthritis group as compared to the control group.
The company said that another benefit of the 18-day model is that synchronicity of disease onset allows coordinated testing, as well as direct comparison between test groups within the same study. Incidence rates approach 100%, reducing group sizes, as well as allowing for more significant read-outs from individual studies.
The ArthritoMab Arthritogenic Antibody Cocktail is comprised of four monoclonal antibodies to collagen type II (CII) that have been chosen for their epitope specificity.